Overview

A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with rheumatoid arthritis (RA).
Phase:
Phase 2
Details
Lead Sponsor:
Human Genome Sciences Inc.
Treatments:
Antibodies
Belimumab